Cinnarizine, a drug capable of improving blood flow, was studied for its action on blood viscosity and its main components in patients affected by peripheral obliterative arterial diseases (POAD). Both acute and chronic administration of the drug diminished the increased whole-blood viscosity in patients, without affecting plasma and serum viscosity, hematocrit, plasma fibrinogen concentration, and plasma osmolality. Since cinnarizine also led to a significant increase of peripheral muscular blood flow, it was hypothesized that this action may be due to an increased deformability of the red cells, and may play a considerable role in the therapeutic approach to POAD.
Introduction
The therapeutic effects of cinnarizine in patients with circulatory disorders have been repeatedly described. Many controlled clinical trials have confirmed the usefulness of the drug both in cerebrovascularl-5 and peripheral obliterative arterial diseases. [6] [7] [8] [9] [10] [11] In a previous paper we demonstrated that in either short-or long-term therapy, cinnarizine increased blood flow in the lower limbs of both patients with obliterative arterial diseases and normal subjects.12 This property of the drug was also noted by Verhaegen et The blood-flow-increasing activity of the pharmacologic agents could be due either to a direct action on the vessel wall followed by a reduction of the circulatory resistance, or to an effect on the blood viscosity. Since cinnarizine undoubtedly influences the peripheral circulation, thus increasing the muscular blood flow, the possibility of a specific effect on blood viscosity can be postulated. The aim of this research was to test this working hypothesis in man.
Materials and Methods
The experiment was designed to study the action of cinnarizine on the blood viscosity after both a single dose and a week of treatment.
Twenty-five subjects affected with peripheral obliterative arterial disease (POAD) of the lower legs and suffering from intermittent claudication were included in the study. They were divided into two groups. The first group, composed of 14 drops). In the single-dose study each subject received 300 mg of cinnarizine orally in the early morning. Blood samples were taken with a plastic syril:ge from an antecubital vein before the administration of the drug, after 90 minutes, and after 180 minutes. In the 1-week study each subject received 75 mg of cinnarizine three times daily for 7 days. Blood samples were taken before the first administration and in the early morning of the eighth day, 8 hours after the last administration of the drug.
Blood samples were treated with the following anticoagulants: 10% EDTA (0.1 ml in 8 ml of blood) for whole blood and plasma viscosity measurements, 3 .8% sodium citrate (0.5 ml in 4.5 ml of blood) for fibrinogen determination, and a minimal amount of heparin sodium for osmolality determination.
In each sample we estimated the following parameters: 
Results
The mean SE results are reported in Table 1 for the single-dose study and in Table 2 for the 1-week study. Statistical analysis was performed by using student's t test for paired variables (the mean values after treatment were compared with mean pretreatment values).
All the subjects affected by POAD had higher blood viscosity values before treatment than the group of 45 normal subjects whom we studied in our laboratory.28 This finding is in keeping with our previous report28 and with the papers of the other authors29-36 who studied blood viscosity in POAD.
In the single-dose study, blood viscosity decreased significantly, 90 minutes, and even more 180 minutes after the administration of the drug. At the 180th minute the percentage of decrease was almost the same at all the shear rates considered, yet slightly more considerable at the lower (3.75 s-1 = 16%) than at the higher rates (750 s-' = 11.7%) (Figure 1) .
A slight decrease was observed in plasma viscosity and fibrinogen concentration, but the changes were not significant. No variations were noted in serum viscosity, hematocrit, or plasma osmolality.
In the 1-week study the results were similar. Blood viscosity decreased in a highly significant manner at all the shear rates considered. As in the single-dose study, the decrease was slightly more considerable at the lower shear rates (3.75 s-1 = 18.3%) than at the higher ones (750 s-1 = 11%) (Figure 2 
